Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP-624 in acute schizophrenia
NCT04510298Phase 1Completed
- Sponsor
- Sirtsei Pharmaceuticals, Inc.
- Start
- Oct 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing SP-624 with Placebo (2 arms). Primary endpoint: Incidence of Adverse Events (AEs) up to 8 weeks. Started Oct 2020; status: completed.
02
Drugs
forvisirvat
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04510298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04510298.